Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

2018 Saw Record Launches, But No Big Splash

Executive Summary

The number of US drug approvals in 2018 was striking, but most of the novel products launched last year are for rare diseases or niche cancers, meaning commercial success may be in the eye of the beholder.

You may also be interested in...



2019 Drug Launches: New Specialty And Rare Disease Blockbusters Take Shape

Novartis' Zolgensma and Pfizer's Vyndaqel were two of the early commercial standouts in 2019, on a likely blockbuster trajectory, while AbbVie's Skyrizi is poised to be fierce competitor in psoriasis.

AbbVie Revs Up The Race To Market In Uterine Fibroids

AbbVie and Neurocrine submitted an NDA to FDA for elagolix for bleeding associated with uterine fibroids, leading in what is expected to be a competitive market.

GSK Gets A Boost From Shingrix And Other New Drugs

The shingles vaccine Shingrix and new HIV and respiratory drugs drove first quarter growth at GlaxoSmithKline, even as Advair and Breo sales were impacted by a generic.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC125022

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel